Abstract: The present disclosure is directed to a compound of formula (I) (E266) and its acceptable pharmaceutical salts, to pharmaceutical compositions comprising the compound and its use in the manufacture of medicaments for treating diseases.

Abstract: The present application is directed to pharmaceutical compositions comprising derivatives of 6-(4-substitutedphenyl)-2-(substituted piperidine)imidazo[2,1-b][1,3,4]thiadiazol-2-yl], to a method of treating cancer using these compositions and to processes for preparing these derivatives.

Abstract: Provided are compositions and methods for modulating selective cell death mechanisms. More specifically, provided are methods and compositions for inducing in a cell or in a subject in need thereof, mitochondrial damage and/or ADP ribosylation activity of PARP using an effective amount of at least one inhibitor of Fer tyrosine kinase (Fer).

Abstract: A balloon adaptor formed from a single piece body for receiving therein a balloon flange. The balloon adaptor has a one-way valve that is located between an inflating opening and a balloon insertion opening. The balloon insertion opening has a forwardly diverging conical surface and ends, in a rearward portion thereof, with a sharp shoulder. The balloon flange abuts against a shoulder abutment surface that holds the balloon attached to the balloon adaptor during inflation of the balloon. The present invention also discloses a balloon release mechanism for easily releasing the inflated balloon from the balloon adaptor.

Abstract: A balloon adaptor formed from a single piece body for receiving therein a balloon flange. The balloon adaptor has a one-way valve that is located between an inflating opening and a balloon insertion opening. The balloon insertion opening has a forwardly diverging conical surface and ends, in a rearward portion thereof, with a sharp shoulder. The balloon flange abuts against a shoulder abutment surface that holds the balloon attached to the balloon adaptor during inflation of the balloon. The present invention also discloses a balloon release mechanism for easily releasing the inflated balloon from the balloon adaptor.

Abstract: An isolated pore-forming polypeptide is disclosed which comprises a naturally-occurring plugging module and a naturally-occurring pore domain, wherein at least one amino acid of the pore-forming polypeptide is mutated to generate a protease cleavage site, serving to at least partially remove the plugging module from the pore domain. The pore forming polypeptides may be inserted into an encapsulating particle and positioned such that it is capable of forming a pore through the lipid layer of the particle in a presence of the protease.

Abstract: Heterocyclic compounds of formula (I), (II), (III) or a pharmaceutically acceptable salt thereof: wherein R1, R2 and R3 are each independently selected from hydrogen, halogen, C1-6alkyl, C2-6alkenyl, N—(C1-6alkyl)2, and N—(C2-6alkenyl)2, the C1-6alkyl and C2-6alkenyl being straight or branched; and Y1 and Y2 are selected from N and CH where one of Y1 and Y2 is N and the other is CH, are provided. Also provided are the synthesis of and pharmaceutical compositions including these compounds. These compounds and pharmaceutical compositions thereof can be used for the treatment of disorders, and in particular, cancer.

Abstract: Provided is a pharmaceutical composition including as an active component a compound of formula (I): wherein X and (R1)n are as defined, and a physiological acceptable carrier. Also provided is a method for treating cancer including administering to an individual in need of such treatment an effective amount of the presently described pharmaceutical composition.

Abstract: An isolated pore-forming polypeptide is disclosed which comprises a naturally-occurring plugging module and a naturally-occurring pore domain, wherein at least one amino acid of the pore-forming polypeptide is mutated to generate a protease cleavage site, serving to at least partially remove the plugging module from the pore domain. The pore forming polypeptides may be inserted into an encapsulating particle and positioned such that it is capable of forming a pore through the lipid layer of the particle in a presence of the protease.

Abstract: Provided are heterocyclic compounds, their synthesis and pharmaceutical compositions including them for the treatment of disorders, in particular, cancer.

Abstract: Provided is a pharmaceutical composition including as an active component a compound of formula (I): wherein X and (R1)n are as defined, and a physiological acceptable carrier. Also provided is a method for treating cancer including administering to an individual in need of such treatment an effective amount of the presently described pharmaceutical composition.

Abstract: Provided is a novel Fer-like protein, referred to as “FerC” (Fer colorectal cancer). FerC is a 47kDa protein having a unique N-terminal sequence and was found to be present in six colon cancer cell-lines and in five hepatocarcinoma (liver cancer) cell-lines, but not in CCD33 normal colon epithelial cells or normal human and mouse fibroblasts. Depletion of FerC impairs cell-cycle progression and induces apoptotic death in treated colon cancer (CC) cells. Also provided are nucleotide sequences that are antisense to at least a portion of the N-terminal sequence, short interfering nucleotides including such an antisense sequence, as well as pharmaceutical compositions containing an antisense sequence. The present pharmaceutical composition may be used in the treatment of cancer, in particular, colorectal cancer and liver cancer.

Abstract: A method for modulating a Fer mediated pathway in a cell, for monitoring the effect of a Fer protein in a cell, for altering and inhibiting one or more effects of a Fer protein in a cell is provided. The method includes modulating, monitoring, altering or inhibiting any one or more or of the association of the Fer protein to PP1; the phosphorylation of PP1, the phosphatase activity of PP1, and the tumor suppressive activity of the retinoblastoma protein (RB). In a preferred embodiment, modulating a Fer mediated pathway in a cell, monitoring the effect of a Fer protein in a cell, for altering and inhibiting one or more effects of a Fer protein in a cell involves administrating to a cell a compound having a molecular weight of up to 1000 Dalton capable of modulating, altering or inhibiting an effect of Fer. Further provided is a method for determining whether a substance is capable of altering or inhibiting an effect of a Fer protein in a cell.

Abstract: Nucleic acid molecules useful in the treatment of cancer are provided. The nucleic acid molecules may include a short interfering ribonucleic acid molecule directed against fer mRNA. A kit for the treatment of cancer including a short interfering ribonucleic acid molecule of the presently described subject matter, as well as a pharmaceutical composition containing a short interfering ribonucleic acid molecule, is also provided. In addition, a method of treating cancer in an individual in which expression of fer in cells or tissues of an individual is inhibited using a short interfering ribonucleic acid molecule is provided.

Abstract: Methods and compositions for the diagnosis, prevention, and treatment of cancer are provided. More particularly, the present invention provides methods and compositions for the diagnosis, prevention, and treatment of cancer through detection and modulation of the expression of TMF/ARA160 and Fer.

Abstract: Methods and compositions for the diagnosis, prevention, and treatment of cancer are provided. More particularly, the present invention provides methods and compositions for the diagnosis, prevention, and treatment of cancer through detection and modulation of the expression of TMF/ARA160 and Fer.